Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 12.1% in October

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 61,000 shares, an increase of 12.1% from the September 30th total of 54,400 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average trading volume of 27,300 shares, the days-to-cover ratio is currently 2.2 days.

Eterna Therapeutics Trading Down 0.9 %

Shares of ERNA traded down $0.01 during mid-day trading on Thursday, reaching $1.09. The company’s stock had a trading volume of 17,058 shares, compared to its average volume of 15,822. The stock has a market cap of $5.90 million, a PE ratio of -0.25 and a beta of 4.39. Eterna Therapeutics has a 52 week low of $0.83 and a 52 week high of $2.63. The company’s fifty day moving average price is $1.30 and its two-hundred day moving average price is $1.70.

Eterna Therapeutics (NASDAQ:ERNA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.02) EPS for the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%. The firm had revenue of $0.05 million for the quarter.

Institutional Investors Weigh In On Eterna Therapeutics

An institutional investor recently raised its position in Eterna Therapeutics stock. Sippican Capital Advisors raised its stake in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) by 34.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,800 shares of the company’s stock after purchasing an additional 18,750 shares during the quarter. Sippican Capital Advisors owned approximately 1.35% of Eterna Therapeutics worth $175,000 at the end of the most recent reporting period. 70.55% of the stock is owned by institutional investors and hedge funds.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.